Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan

2018 ◽  
Vol 37 (2) ◽  
pp. 273-281 ◽  
Author(s):  
Hiroshi Hagino ◽  
Satoshi Soen ◽  
Toshitsugu Sugimoto ◽  
Naoto Endo ◽  
Ryo Okazaki ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Osteoporosis ◽  
Multicenter Study ◽  
Bisphosphonate Treatment

Predictors of Sinonasal Quality of Life and Nasal Morbidity after Endoscopic Transsphenoidal Surgery: A Multicenter Study

2015 ◽  
Vol 76 (S 01) ◽  
Author(s):  
Andrew Little ◽  
Daniel Kelly ◽  
John Milligan ◽  
Chester Griffiths ◽  
Ricardo Carrau ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multicenter Study ◽  
Transsphenoidal Surgery ◽  
Endoscopic Transsphenoidal Surgery

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

2014 ◽  
Vol 23 (01) ◽  
pp. 49-55
Author(s):  
L. C. Hofbauer ◽  
D. Felsenberg ◽  
M. Amling ◽  
A. Kurth ◽  
P. Hadji
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Osteoporosis ◽  
Primary Outcome ◽  
Osteoporosis Treatment ◽  
Secondary Outcome ◽  
Matched Pairs ◽  
Fracture History ◽  
Baseline Characteristics ◽  
Study Inclusion

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

scholarly journals Reprint of: Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries

2019 ◽  
Vol 112 (4) ◽  
pp. e137-e152 ◽  
Author(s):  
Kelechi E. Nnoaham ◽  
Lone Hummelshoj ◽  
Premila Webster ◽  
Thomas d'Hooghe ◽  
Fiorenzo de Cicco Nardone ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multicenter Study ◽  
Work Productivity

scholarly journals Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany

2020 ◽  
pp. 1-13
Author(s):  
Niels Teich ◽  
Michael Bläker ◽  
Frank Holtkamp-Endemann ◽  
Eric Jörgensen ◽  
Andreas Stallmach ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Multicenter Study ◽  
Work Productivity ◽  
Infliximab Treatment ◽  
Prospective Multicenter Study ◽  
Hospitalization Rates ◽  
The Mean

<b><i>Introduction:</i></b> Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients’ quality of life in an economically sensible way is conflicting so far. <b><i>Methods:</i></b> We conducted a noninterventional, multicenter, open-label, prospective study to evaluate the effect of originator IFX treatment on patient-reported outcomes and disease-related hospitalizations in adult CD patients in Germany treated for the first time with IFX according to label. <b><i>Results:</i></b> Two hundred and ninety-four patients were included in the study. We observed a statistically significant reduction in the number of CD-related hospitalizations from the year before baseline (mean 1.00 per patient, SD ± 0.93) to the mean value of the 1st (0.62, SD ± 0.95) and 2nd year (0.32, SD ± 0.75) of the observation period (<i>p</i> &#x3c; 0.0001). After 3 months of IFX therapy, work productivity and activity increased by an average of 12.6 and 17.1%, respectively. Patient’s clinical outcome was markedly improved as the total CD activity index (CDAI) sum score continuously decreased from baseline to month 24 and the mean score of the total inflammatory bowel disease questionnaire (IBDQ) changed substantially from 141 at baseline to 172 after 24 months of IFX treatment. Additionally, the number of work incapacity days declined. Recently, no new safety issues of IFX have been identified. <b><i>Conclusion:</i></b> In this large, prospective, multicenter study on disease-related hospitalization rates, work productivity, capacity for daily activities, and HRQoL in patients with CD, IFX significantly reduces their hospitalization rates and improves work productivity, daily activity, and quality of life over 24 months.

Multicenter study of peroneal mononeuropathy: clinical, neurophysiologic, and quality of life assessment

2005 ◽  
Vol 10 (3) ◽  
pp. 259-268 ◽  
Author(s):  
Irene Aprile ◽  
Pietro Caliandro ◽  
Giuseppe La Torre ◽  
Pietro Tonali ◽  
Mariangela Foschini ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multicenter Study ◽  
Life Assessment ◽  
Quality Of Life Assessment

scholarly journals Quality of Life in People with Young-Onset Dementia: A Nordic Two-Year Observational Multicenter Study

2019 ◽  
Vol 67 (1) ◽  
pp. 197-210 ◽  
Author(s):  
Lara Hvidsten ◽  
Knut Engedal ◽  
Geir Selbæk ◽  
Torgeir Bruun Wyller ◽  
Jūratė Šaltytė Benth ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multicenter Study ◽  
Young Onset ◽  
Young Onset Dementia
Sign in / Sign up

Export Citation Format

Share Document